Early research (Phase 1)WithdrawnNCT05037669
What this trial is testing
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma
Who this might be right for
Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
University of Pennsylvania